Drug firm Gilead is outraged after finding from WHO remdesivir trial
Gilead Sciences says the findings appear inconsistent with evidence from other studies validating the clinical benefit of remdesivir
16 October 2020 - 18:01
Zurich/Geneva — A row broke out on Friday over a World Health Organisation (WHO) clinical trial which concluded that the antiviral drug remdesivir has little or no impact on a patient’s chances of surviving Covid-19.
Gilead Sciences, the US company that developed the drug, said the findings appeared inconsistent with evidence from other studies validating the clinical benefit of remdesivir, which was used to treat US President Donald Trump’s coronavirus infection...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.